Phase I/II study of biweekly administration regimen of paclitaxel combined with CPT-11 [irinotecan] in patients with second line chemotherapy of inoperable or recurrent gastric cancer

Trial Profile

Phase I/II study of biweekly administration regimen of paclitaxel combined with CPT-11 [irinotecan] in patients with second line chemotherapy of inoperable or recurrent gastric cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2009

At a glance

  • Drugs Irinotecan (Primary) ; Paclitaxel (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top